Thr724
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Thr724 - APP iso8 (human)

Site Information
VEVDAAVtPEERHLS    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: APP iso2 (mouse): T668, APP (mouse): T743, APP iso4 (human): T668, APP iso2 (rat): T668, APP (rat): T743, APP (human): T743
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: mutation of modification site (2), phospho-antibody (1), western blotting (1)
Disease tissue studied: brain cancer (2), glioblastoma (2), glioma (2), sporadic inclusion-body myositis (1)
Relevant cell line - cell type - tissue: 'muscle, skeletal' (1), U87MG (glial) (2)

Controlled by
Treatments: epoxomicin (1), lithium (1), thapsigargin (1), tunicamycin (1)



References

1

Terracciano C, Nogalska A, Engel WK, Askanas V (2010) In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 112, 389-96
19878439   Curated Info

2

Jacobsen JS, et al. (1994) The release of Alzheimer's disease beta amyloid peptide is reduced by phorbol treatment. J Biol Chem 269, 8376-82
8132561   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.